Drugs / Sanaria® PfSPZ Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04940130 | Apr → Dec 2022 | Plasmodium falciparum malaria | Sanaria Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2017-01-12 | Sanaria Inc. | Results Sanaria’s PfSPZ Vaccine Provides High-Level Defense Against Malaria In U.S. Navy and Army Clinical Investigation sanaria.com ↗
Furthermore, protection was achieved with just three doses of the vaccine and against a strain of parasite similar to one in the vaccine for at least 24 weeks. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2017-01-12 | Sanaria Inc. | Sanaria’s PfSPZ Vaccine Provides High-Level Defense Against Malaria In U.S. Navy and Army Clinical Investigation sanaria.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sanaria PfSPZ Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04940130 ↗ |
| Modality | Vaccine | “whole sporozoite (SPZ) vaccine” NCT04940130 ↗ |
| Route | Intravenous | “via direct venous inoculation (DVI)” NCT04940130 ↗ |